Fungal prosthetic joint infection in total hip or knee arthroplasty: a retrospective single-centre study of 26 cases.


Journal

The bone & joint journal
ISSN: 2049-4408
Titre abrégé: Bone Joint J
Pays: England
ID NLM: 101599229

Informations de publication

Date de publication:
05 2019
Historique:
entrez: 1 5 2019
pubmed: 1 5 2019
medline: 16 5 2019
Statut: ppublish

Résumé

Fungal prosthetic joint infections (PJIs) are rare and account for about 1% of total PJIs. Our aim was to present clinical and microbiological results in treating these patients with a two-stage approach and antifungal spacers. We retrospectively reviewed our institutional database and identified 26 patients with positive fungal cultures and positive Musculoskeletal Infection Society (MSIS) criteria for PJI who were treated between 2009 and 2017. We identified 18 patients with total hip arthroplasty (THA) and eight patients with total knee arthroplasty (TKA). The surgical and antifungal treatment, clinical and demographic patient data, complications, relapses, and survival were recorded and analyzed. The median follow-up was 33 months. The success rate was 38.5% (10/26). Fluconazole resistance was found in 15%. Bacterial co-infection was common in 44% of patients for THA and 66% of patients with TKA. Mortality, reoperations, and treatment failure were common complications. Treatment with a two-stage exchange is a possible option for treatment, although fungal infections have a high failure rate. Therapeutic factors for treatment success remain unclear. Cite this article:

Identifiants

pubmed: 31038988
doi: 10.1302/0301-620X.101B5.BJJ-2018-1227.R2
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

589-595

Auteurs

C Theil (C)

Department of Orthopedics and Tumour Orthopedics, Muenster University Hospital, Muenster, Germany.

T Schmidt-Braekling (T)

Department of Orthopedics and Tumour Orthopedics, Muenster University Hospital, Muenster, Germany.

G Gosheger (G)

Department of Orthopedics and Tumour Orthopedics, Muenster University Hospital, Muenster, Germany.

E A Idelevich (EA)

Institute of Medical Microbiology, Muenster University Hospital, Muenster, Germany.

B Moellenbeck (B)

Department of Orthopedics and Tumour Orthopedics, Muenster University Hospital, Muenster, Germany.

R Dieckmann (R)

Department of Orthopedics and Tumour Orthopedics, Muenster University Hospital, Muenster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH